Resembling a new era of innovative drug development, the interest of the biopharma industry in the peptide and oligonucleotide markets has risen significantly in the past five years. The advent of oral and inhaled peptide products has driven demand for these active pharmaceutical ingredients (APIs).

Between 2018 and 2020, the average peptide manufacturing batch size increased by 2.3 times in response to a wider variety of peptide drug modalities entering the market. Furthermore, with the launch of new glucagon-like peptide (GLP) analogs targeting metabolic diseases like diabetes and obesity, there is a growing need for large-scale manufacturing of these APIs to treat a large patient population.